ArticleBlood2021

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia.

Steven P Treon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.